Drug Approval | October 21, 2025
FDA approves Tezspire for chronic rhinosinusitis with nasal polyps
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
The approval follows robust data from the SWIFT and ANCHOR Phase III trials
Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally
Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway
Subscribe To Our Newsletter & Stay Updated
